Pliva has continued its rapid expansion with the opening of a new
R&D facility in the USA that will carry out formulation work on
generic pharmaceuticals.
Amersham trimmed its 2003 profit forecast by £40 million (€57m), or
4.1 pence per share, after reporting lower sales and pre-tax
profits for the first half of 2003.
EPIDAUROS Biotechnologie has acquired a non-exclusive licence for
the diagnostic use of one of the most important genetic variants of
the cytochrome P450 2D6 gene.
The European Commission sends written warnings to France, Belgium
and the Netherlands for failing to comply with its regulations on
animal experiments.
Vencor has launched a range of chemical taggants that can be used
to provide secure identification of products, including drugs and
speciality chemicals.
DSM reports a disappointing set of second quarter results and says
it is unlikely to meet its 2002 operating profit level this year;
the group blames weaker demand for its products and negative
currency factors. Restructuring drive...
Scientists have developed a way of making proteins in sugarcane
that they claim will be safe and less expensive than transgenic
approaches using animals.
LGC has acquired Germany's Mikromol, a specialist in pharmaceutical
impurities and metabolites used as reference materials, to create
its first non-UK lab.
